Physician profile
Peter J Freitag
NPI 1023372463
$3,308.78
in general payments reported to CMS, 2019-2025
18 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $242 · 2021: $158 · 2022: $1,463 · 2023: $529 · 2024: $271 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.36 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,365.51 | 2022-2025 | |
| Alcon Vision LLC | $494.05 | 2019-2025 | Wavelight Plus, Precision7, Total30 |
| Coopervision INC. | $203.25 | 2023-2025 | Myday Contact Lens, Cvi Contact Lens, Misight Contact Lens |
| Rxsight INC | $148.90 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $122.21 | 2024 | Infuse |
| Sight Sciences, INC. | $117.82 | 2023 | Tearcare System |
| Allergan, INC. | $116.36 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.79 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $99.66 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $79.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $76.95 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $58.72 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $52.74 | 2019-2020 | |
| Abbvie INC. | $50.00 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $39.10 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $25.00 | 2019 | |
| Shire North American Group INC | $21.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Freitag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.